Anti-ADAM17 [17MOCYT]

As proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis.

Contributors

Inventor Institute
Carl Blobel Hospital for Special Surgery
SKU: 152533
Product description: ADAM17 (TACE/CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis.
Conjugation: Unconjugated
Molecular weight: ~100 kDa (mature form), ~120 kDa (pro-form)
Immunogen: GST-cyto corresponding to the cytoplasmic domain of murine ADAM17
Cat. #: 152533
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cancer;Cell signaling and signal transduction;Metabolism;Neurobiology;Stem cell biology
Application: WB
Target: ADAM17
Reactivity: Mouse
Clone: 17MOCYT
Host: Rabbit
Class: Polyclonal
Target background: ADAM17 (TACE/CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis.
Format: Liquid
Concentration: 0.9-1.1 mg/ml
Storage buffer: Whole serum
Storage conditions: -20° C
Shipping conditions: Dry ice
References:

Horiuchi et al. 2007. J Immunol. 179(5):2686-9. PMID: 17709479.

Le Gall et al. 2010. J Cell Sci. 123(Pt 22):3913-22. PMID: 20980382.

Maretzky et al. 2011. Nat Commun. 2:229. PMID: 21407195.

Schlndorff et al. 2000. Biochem J. 347 Pt 1:131-8. PMID: 10727411.

Zheng et al. 2002. J Biol Chem. 277(45):42463-70. PMID: 12207026.

Images

View Gallery
Western blot analysis using Anti-ADAM17

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.